



## **Report of the Sixth Meeting of the Pandemic Influenza Preparedness (PIP) Framework 2016 Review Group**

### **ORGANIZATION AND PROCESS OF THE MEETING**

1. The sixth meeting of the PIP Framework Review Group was held at WHO Headquarters from 29 August to 2 September 2016. The meeting included in its agenda:
  - Consultation with Member States and Stakeholders;
  - Discussion of the draft WHO study into the public health implications of implementation of the Nagoya Protocol;
  - Discussions with key WHO informants;
  - Discussions on the Review Group's draft Final Report, including Findings and Recommendations;
  - Webcast of key messages from the meeting.
2. Seven of the eight members of the Review Group, attended the meeting (names and affiliations of the members are listed in Annex 1). Dr Christine Mwelwa Kaseba-Sata, the Chair, was absent and sent apologies.

### **OPENING OF THE MEETING**

3. Dr Theresa Tam was selected as acting chair for the meeting in the absence of Dr Kaseba-Sata. Dr Tam welcomed members to the meeting and outlined the agenda.

### **OPEN CONSULTATION WITH MEMBER STATES**

4. Dr Peter Salama, Executive Director of WHO's new Health Emergencies Programme, welcomed Member States to the consultation session and provided a brief overview of the PIP Review Group, the importance of its work, and the extensive consultations with, and input from, Member States since the Review Group started work eight months ago. He thanked stakeholders for their commitment and efforts during the PIP Review process.
5. Around 30 Member States attended the consultation meeting. Several provided comments to the Review Group on the draft Findings that had been provided in advance of the consultation event, while others indicated they would soon provide written submissions. Various topics were raised during discussions, including:

- The future relationship between the PIP Framework and WHO's new Health Emergencies Programme;
  - The arguments for and against extending the scope of the PIP Framework to cover seasonal influenza;
  - Whether there was a need to consider rewording parts of the PIP Framework in order to remove ambiguities;
  - The importance of the PIP Framework as a tool to secure global pandemic influenza preparedness;
  - The need for greater clarity regarding the reasons for the apparent decline in virus sharing over recent years and the PIP Framework Secretariat's ongoing investigations in this area;
  - The status of the PIP Framework as the outcome of an intergovernmental process and the necessary role of Member States in deciding any future functional changes to the Framework;
  - The linkages and relationship between the IHR and the PIP Framework;
  - The challenges of negotiating SMTA2s (Standard Material Transfer Agreement 2s) and of securing agreements from all those entities that should be contributing to benefit sharing;
  - The need to encourage industry to include technology transfer and other forms of technological cooperation as part of PIP Framework SMTA2 benefit sharing offers;
  - The different approaches through which the use of genetic sequence data (GSD) for influenza viruses with human pandemic potential (IVPP) could be traced in order to implement associated benefit sharing obligations under the PIP Framework.
6. Dr Tam responded to Member States' points and added that the Review Group would continue to work on its draft Findings. Member States were requested to submit any final written submissions by 12 September 2016.
  7. A number of Member States thanked the Review Group for its consultation process with Member States and other stakeholders.

#### **OPEN CONSULTATION WITH MEMBER STATES AND STAKEHOLDERS**

8. Dr Tam welcomed participants to the open consultation session and welcomed feedback to the Review Group on the draft Findings.
9. Dr Margaret Chan, WHO Director-General, thanked the Review Group and stakeholders, and emphasized the transparent and open manner in which the Review had been conducted to date. Dr Chan said Member States were enthusiastic about the PIP Framework and she was looking forward to receiving the Review Group's Final Report, for onward transmission to the WHO Executive Board and then to the World Health Assembly in May 2017.
10. Participants at this open consultation session included representatives from industry, a GSD database, a non-governmental organization, a WHO Collaborating Centre and a health profession organization; Member States also attended this session.
11. Stakeholders provided a number of comments, which covered a range of subjects including:

- How the sharing of IVPP GSD should trigger benefit sharing and the various options for tracking the use of GSD;
- The role that open and timely access to GSD has in research and development;
- The arguments for and against extending the scope of the PIP Framework to cover seasonal influenza;
- The amount collected from industry under the Partnership Contribution benefit sharing mechanism;
- The relationship between the PIP Framework and the Nagoya Protocol;
- Whether seasonal vaccine production, as a pathway to pandemic vaccine production, should be included in the next Partnership Contribution implementation plan.
- The need to prioritize that all major vaccine manufacturers conclude SMTA 2s, given the fact that some large companies have yet to sign agreements.
- The importance that the PIP Secretariat's study into the reasons behind the recent decline in virus sharing talk to GISRS laboratories as part of its effort to understand why not all IVPP samples are being shared.
- The need for a choice for data providers as to how they share GSD, given the different types of databases in operation;
- The suggestion that an external audit would be useful for reporting how the Partnership Contribution funds have been spent.

12. Dr Tam and other Review Group members responded to stakeholders' points and stakeholders were requested to submit any final written submissions by 12 September 2016.

13. Dr Tam thanked participants for attending the open consultation session.

#### **ANALYSIS OF MEMBER STATE AND STAKEHOLDER SUBMISSIONS TO THE REVIEW GROUP**

14. The Review Group analyzed the contributions received from Member States and Stakeholders during the two consultation sessions, as well as the written submissions received to date in response to the Group's draft Findings.

#### **DISCUSSION OF THE FINAL REPORT**

15. The Review Group reviewed in detail each section of the draft Final Report, including discussion of the draft Findings and Recommendations.

#### **NEXT STEPS**

16. The Review Group considered next steps, including the process for reviewing the final submissions from Member States and other stakeholders, and the schedule for final revisions to and completion of the draft Final Report, ahead of submission to the WHO Director-General in October 2016.

17. The Review Group approved the meeting report, and the acting Chair thanked the members and closed the meeting.

#### **WEBCAST OF KEY MESSAGES FROM THE MEETING**

18. The Review Group held a webcast information session for Member States, summarizing the key outcomes of the meeting and inviting further participation by Member States and stakeholders in the process.

## ANNEX 1

### MEMBERS OF THE REVIEW COMMITTEE

Review Group Members	Affiliation
Professor William Kwabena Ampofo	Head of Virology Department, Noguchi Memorial Institute for Medical Research, University of Ghana, Accra, Ghana
Dr Christine Mwelwa Kaseba-Sata (Chair)	Former WHO Goodwill Ambassador against Gender-based Violence, Zambia
Dr Frances McGrath	Chief Advisor, Office of the Chief Medical Officer, Ministry of Health, New Zealand
Dr Talat Mokhtari-Azad	Director, Iranian National Influenza Center
Ms Johanne Newstead	Head of Food Policy, Public Health Directorate, Department of Health, United Kingdom
Dr Theresa Tam	Assistant Deputy Minister, Infectious Disease Prevention and Control Branch, Public Health Agency of Canada
Dr Viroj Tangcharoensathien	Senior Adviser, International Health Policy Program, Ministry of Public Health, Thailand
Prof Dr Makarim Wibisono	Chairman, Governing Board of Indonesia Council of World Affairs